Noninvasive Liver Tests Position HepQuant DuO as a noninvasive, quantitative liver health test that helps clinicians assess liver function and portal-systemic shunting, enabling earlier, risk-informed decisions about invasive procedures and treatments.

Clinical Value Focus Highlight how DuO and its Disease Severity Index support monitoring treatment response, predicting disease progression, and anticipating adverse outcomes, which can drive adoption in hepatology practices and specialties.

Clinical Conference Momentum Leverage recent conference activity and publications at EASL, The Liver Meeting, MASH events, and DDW to pursue partnerships with academic centers, key opinion leaders, and CROs for broader validation and studies.

Expansionible Platform Emphasize the test’s growing clinical availability and added value in diverse settings, presenting opportunities to integrate with hospital information systems (likely via Salesforce) and expand adoption across liver clinics and research sites.

Funding and Growth Signals Target midmarket liver disease centers and contract research organizations given the company’s revenue range and active trials, offering collaboration on multi-site studies, reimbursement pathways, and payer engagement to scale usage.